Drugs / TMV vaccine
last change Dec 2025 re-read 2 minutes ago

TMV vaccine

Vaccine

Developed for
female breast carcinoma · triple-negative breast carcinoma
Investigated by
Emory University · National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06324240 Dec 2025 → Dec 2026 expected female breast carcinoma, triple-negative breast carcinoma Emory University Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TMV vaccine “Given TMV vaccine ID” NCT06324240
Modality Vaccine “personalized vaccine (tumor membrane vesicle or TMV vaccine)” NCT06324240